Literature DB >> 21360133

Irinotecan is inactive as a first-line treatment, but plays an important part in gastric cancer treatment.

Hiroya Takiuchi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21360133     DOI： 10.1007/s10120-011-0018-4

Source DB:  PubMed          Journal:  Gastric Cancer        ISSN： 1436-3291            Impact factor:   7.370


× No keyword cloud information.
  5 in total

1.  S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

Authors:  Wasaburo Koizumi; Hiroyuki Narahara; Takuo Hara; Akinori Takagane; Toshikazu Akiya; Masakazu Takagi; Kosei Miyashita; Takashi Nishizaki; Osamu Kobayashi; Wataru Takiyama; Yasushi Toh; Takashi Nagaie; Seiichi Takagi; Yoshitaka Yamamura; Kimihiko Yanaoka; Hiroyuki Orita; Masahiro Takeuchi
Journal:  Lancet Oncol       Date:  2008-02-20       Impact factor: 41.316

2.  Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.

Authors:  Narikazu Boku; Seiichiro Yamamoto; Haruhiko Fukuda; Kuniaki Shirao; Toshihiko Doi; Akira Sawaki; Wasaburo Koizumi; Hiroshi Saito; Kensei Yamaguchi; Hiroya Takiuchi; Junichiro Nasu; Atsushi Ohtsu
Journal:  Lancet Oncol       Date:  2009-10-07       Impact factor: 41.316

3.  Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.

Authors:  M Dank; J Zaluski; C Barone; V Valvere; S Yalcin; C Peschel; M Wenczl; E Goker; L Cisar; K Wang; R Bugat
Journal:  Ann Oncol       Date:  2008-06-16       Impact factor: 32.976

4.  Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).

Authors:  Atsushi Ohtsu; Yasuhiro Shimada; Kuniaki Shirao; Narikazu Boku; Ichinosuke Hyodo; Hiroshi Saito; Noboru Yamamichi; Yoshinori Miyata; Nobumasa Ikeda; Seiichiro Yamamoto; Haruhiko Fukuda; Shigeaki Yoshida
Journal:  J Clin Oncol       Date:  2003-01-01       Impact factor: 44.544

5.  Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002).

Authors:  Hiroyuki Narahara; Hiroyasu Iishi; Hiroshi Imamura; Akira Tsuburaya; Keisho Chin; Haruhiko Imamoto; Taito Esaki; Hiroshi Furukawa; Chikuma Hamada; Yuh Sakata
Journal:  Gastric Cancer       Date:  2011-02-23       Impact factor: 7.370
  5 in total
  1 in total

1.  Silencing of XB130 is associated with both the prognosis and chemosensitivity of gastric cancer.

Authors:  Min Shi; Weizhen Huang; Li Lin; Dayong Zheng; Qiang Zuo; Lin Wang; Nina Wang; Yajun Wu; Yulin Liao; Wangjun Liao
Journal:  PLoS One       Date:  2012-08-23       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.